Big demand, smaller dollars
- Wegovy Pill passed 1 million users within 16 weeks, showing demand is not the problem.
- 2026 adjusted sales are guided to fall 4% to 12% at constant exchange rates because price and mix are biting.
- Novo lost the US weekly prescription lead in both diabetes GLP-1 and obesity GLP-1 markets to a competitor.
- CagriSema, high-dose Wegovy, and oral launches keep the pipeline story alive.
- The stock looks less demanding than before, but growth and execution still need proof.
Demand is winning, price is not
Novo Nordisk is still one of the main companies in the GLP-1 drug boom. GLP-1 drugs help control blood sugar and can reduce appetite. Ozempic treats type 2 diabetes. Wegovy treats obesity. The new Wegovy Pill launched in the US in early 2026 and passed 1 million users within 16 weeks.
The bull case is simple. Novo has more than one shot on goal. Wegovy High-Dose 7.2 mg launched in the US in April 2026, and trial data showed 20.7% mean weight loss. CagriSema has also shown strong weight loss in Phase 3 trials, including 14.2% in REIMAGINE 2. If oral Wegovy keeps scaling and CagriSema can stand up to tirzepatide, Novo can defend a large share of obesity care.
The bear case is also real. In Q1 2026, adjusted sales fell 4% because lower realized prices offset GLP-1 volume growth. Management now guides 2026 adjusted sales to decline 4% to 12% at constant exchange rates. That is a harsh reset for a company that was treated like a hyper-growth story.
The current view is balanced but cautious. Novo has powerful products and a deep pipeline, yet it has lost US volume leadership in both diabetes and obesity GLP-1 prescriptions. The next test is whether cheaper access creates enough volume to beat lower price per patient.
Patents, payers, and volume
Novo makes money by discovering, manufacturing, and selling prescription medicines. Its biggest business is Obesity and Diabetes care. The company reports two business segments: Obesity and Diabetes care, and Rare disease.
The model works best when patented drugs get broad insurance coverage at strong net prices. Novo then sells large volumes through pharmacies, health plans, and national health systems. That model is now under pressure in the US, where pharmacy benefit managers, Medicare, Medicaid, and cash-pay channels are pushing prices lower.
Novo is trying to trade price for reach. It launched a $499 self-pay Wegovy option through NovoCare and has used even lower starter pricing to pull patients away from compounders. That can protect the brand, but it lowers revenue per prescription.
Management also cut costs. A transformation program reduced about 9,000 positions and targets DKK 8 billion in annual savings. Novo is using deals to widen the pipeline, including Akero for MASH and Omeros for rare blood disorders, while also pursuing Metsera to add more obesity assets.
The drugs that matter
Ozempic and Rybelsus
These semaglutide drugs treat type 2 diabetes. Ozempic had more than DKK 127 billion of global sales in 2025, but US pricing is now eroding by 10% to 15%.
Wegovy and Wegovy Pill
Wegovy is Novo's main obesity brand. Wegovy revenue grew 36% to DKK 79 billion in 2025, and the US Wegovy Pill launch passed 1 million users within 16 weeks.
Wegovy High-Dose 7.2 mg
This higher-dose semaglutide obesity product launched in the US in April 2026. The step-up trial showed 20.7% mean weight loss.
Insulin products
Insulin is Novo's original business and still matters in diabetes care. It is more mature and faces payer pressure and biosimilar competition in some markets.
Rare disease
This includes growth hormone and haemophilia products. It is much smaller than Obesity and Diabetes care, but it adds some spread beyond GLP-1 drugs.
CagriSema
CagriSema combines semaglutide with cagrilintide. It showed 14.2% weight loss in REIMAGINE 2, and investors are watching REDEFINE 4 against tirzepatide.
Akero efruxifermin and Omeros zaltenibart
These acquired assets push Novo further into MASH and rare blood disorders. They broaden the pipeline, but they still need clinical and regulatory proof.
One segment dominates
Novo's 2025 Form 20-F says Obesity and Diabetes care made more than 90% of sales. The shares below use that disclosure, with the balance shown as Rare disease.
What could break the thesis
Lower prices beat higher volume
High impact · High oddsNovo is gaining many new patients, but revenue is still falling because net prices are lower. Q1 2026 adjusted sales fell 4%, and management guides a 4% to 12% adjusted sales decline for 2026. Ozempic in the US is also seeing 10% to 15% price erosion.
Lilly keeps taking GLP-1 share
High impact · High oddsNovo has lost the US weekly prescription lead in both diabetes GLP-1 and obesity GLP-1 markets to a competing GLP-1 product. That changes the story from easy category growth to a price and access fight. A strong CagriSema readout could help, but weak data would make the gap harder to close.
Compounders keep patients away
Medium impact · Medium oddsCompounding pharmacies have sold unapproved copies of GLP-1 drugs in the US. Novo says compounding continued even after the GLP-1 shortage was resolved. The company is fighting back with cash-pay options, but that also pulls more patients into lower-price channels.
Coverage gets narrower
High impact · Medium oddsObesity medicine coverage depends on employers, pharmacy benefit managers, Medicare, Medicaid, and state budgets. Some state Medicaid programs, including California, have pulled back coverage for anti-obesity medicines. Medicare Part D access could help in mid-2026, but it may come with lower prices.
Semaglutide patents and generics
Medium impact · Medium oddsNovo says semaglutide products face patent and exclusivity challenges in some markets. Canada is a named concern for generic semaglutide loss of exclusivity in 2026. Even if the US compound patent runs longer, international erosion can still slow growth.
Pipeline does not clear the bar
Medium impact · Medium oddsNovo needs new drugs and new versions of old drugs to defend its obesity franchise. CagriSema, oral semaglutide launches outside the US, and next-generation assets carry clinical, supply, and approval risk. The FDA Complete Response Letter for Wegovy FlexTouch is a reminder that execution can slip.
In one breath
Is Novo Nordisk still a growth company?
The patient demand is still strong, especially for Wegovy Pill. But 2026 adjusted sales are guided to fall 4% to 12%, so the growth story now depends on price stabilizing and new products scaling.
Why are sales falling if GLP-1 demand is high?
More patients are using the drugs, but Novo is getting less money per patient in key US channels. Lower self-pay prices, Medicare and Medicaid pressure, rebates, and competition are offsetting volume growth.
What is the main catalyst for Novo Nordisk?
CagriSema is the biggest pipeline catalyst, especially REDEFINE 4 against tirzepatide. Investors are also watching Medicare Part D obesity reimbursement and the commercial ramp of Wegovy Pill.
What is the biggest risk for NVO stock?
The biggest risk is that Novo keeps adding patients but cannot protect net price. If that happens, earnings can disappoint even while GLP-1 prescriptions grow.